Navigation Links
Escalon(R) Reports Third Quarter Fiscal 2009 Results
Date:5/19/2009

WAYNE, Pa., May 19 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced results for its fiscal third quarter ended March 31, 2009.

For the third quarter of fiscal 2009, the Company reported increased net revenue of $9,205,000, compared with $8,188,000 in the third quarter of fiscal 2008. This included product revenue of $9,174,000 for the third quarter of fiscal 2009, a 12.7% increase, compared with $8,139,000 in the prior year's third quarter.

The Company experienced continued customer demand at its Drew and EMI business units, which reported 2009 third quarter product revenue growth of 41.4% and 88.5%, respectively, compared with the same period last fiscal year. This growth was offset by decreased 2009 third quarter sales in the Sonomed, Vascular and Medical/Trek business units of 11.9%, 30% and 4%, respectively.

For the nine-month period ended March 31, 2009, the Company reported net revenue of $26,001,000, compared with $22,576,000 in the prior year comparable period. Product revenue increased approximately 15.5% to $25,904,000 during the nine-month period ended March 31, 2009, compared with $22,422,000 in the same period last fiscal year. The growth was driven by increased product revenue within three of the Company's business units, highlighted by 33.8% at Drew, primarily related to the acquisition of JAS Diagnostics in May 2008 and Biocode Hycel in December 2008. Sonomed and EMI product revenue increased 1.1% and 32.5%, respectively.

For the third quarter of fiscal 2009, the Company reported a net loss of $(683,173), or $(0.09) per diluted share, compared with net loss of $(1,942,622), or $(0.30) per diluted share, in the third quarter of fiscal 2008. Operating results were impacted by lower cost of goods sold, which totaled approximately $4,729,000, or
'/>"/>

SOURCE Escalon Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Escalon(R) Reports Second Quarter Fiscal 2009 Results
2. Escalon(R) Medical Corp. Completes Bolt-On Acquisition, Enhances Market Position in France and Expands Product Offering
3. Escalon(R) Medical Corp. Completes $1.1 Million Private Equity Financing
4. Escalon(R) Reports First Quarter Fiscal 2009 Results
5. Escalon(R) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
6. Escalon(R) Enhances Position Within IVD Reagent Market with Strategic Acquisition of JAS Diagnostics
7. Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
8. Escalon(R) Announces Executive Promotions
9. Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System
10. Escalon(R) Reports First Quarter Fiscal 2008 Results
11. Escalon(R) Reports Financial Results for 2007 Fiscal Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... (PRWEB) May 20, 2013 According to a ... Warnings at Indoor Tanning Salons,” tanning salons in ... The Food and Drug Administration wants to see cancer warnings ... a minimum age floor of eighteen for the use of ... concerns about melanoma, which has become increasingly common over the ...
(Date:5/20/2013)... According to a June 2009 Bloomberg article, ... amount to approximately $3.6 billion dollars per year (i). ... estimated that there 15 million incidents of medical harm ... everyone who receives any form of medical treatment should ... Merriam-Webster defines malpractice as “a dereliction of professional duty ...
(Date:5/20/2013)... Osborn’s Brain: Imaging, Pathology, and ... Osborn’s 1993 award winning book Diagnostic Neuroradiology (a.k.a. “The ... neuroradiology texts. , In this highly anticipated 1,300-page ... complex topics visually appealing and easy to understand. It ... with spectacular pathology examples, relevant anatomy, and the most ...
(Date:5/20/2013)... Galveston researchers have been awarded a five-year, $1.8 million ... Stroke to apply the techniques of gene therapy to ... that arises from a malfunction in the nervous system. ... millions of Americans, manifesting itself in a variety of ... intense discomfort in response to a light touch, for ...
(Date:5/20/2013)... 20, 2013 Horizon NJ Health, New ... announced that it has earned a Commendable Accreditation ... Horizon NJ Health is a wholly owned subsidiary of ... , NCQA Health Plan Accreditation is a nationally recognized ... that health plans provide to their members. Health Plan ...
Breaking Medicine News(10 mins):Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2Health News:Osborn’s Brain from Amirsys Publishing Receives Doody’s Top Honors 2Health News:Pain, pain, go away 2Health News:Pain, pain, go away 3Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3
... HIV positive girls will participate ,A beauty contest with ... 2005, which is the World AIDS Day, in which only ... ‘Miss Positive-2005’. The object of the contest is to change ... and also help HIV infected people lead a normal life. ...
... to two genes, both variant forms of a gene called ... in the smoking addiction.// The protein product of these genes ... the body. ,The two identified gene forms are ... metabolism of nicotine, more specifically found to account for slow ...
... heart failure patients in United States have better short-term ... over time.// ,Their study findings appear in the ... ,Heart failure is the most common cause of hospitalization ... ,The authors compared process of care and 30-day ...
... effective treatment option for patients with liver cancer. A ... to treat a patient who harbors a liver tumor ... surgical options are currently available for this group of ... the researchers who have now suggested a novel plan ...
... has found that besides being really harsh on the ears, ... Writing in the latest issue of the European Heart Journal ... mean an increased risk of heart attack. ,Researchers ... study between 1998 and 2001 in 32 hospitals in Berlin. ...
... (QBI) have now found a process that could lead ... and acquired brain injury. ,The research focuses on ... memory function and where the brain's ability to regenerate ... ,The study by Dr Natalie Bull and Professor ...
Cached Medicine News:Health News:Tendency To Smoke and Get Addicted Could Run In Families! 2Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Novel Treatment Found To Prolong Survival Of Liver Cancer Patients 2Health News:Irritating Noise Increases Risk Of Heart Attacks 2Health News:Research Targets treatment for dementia and brain injuries 2
(Date:5/20/2013)... ATLANTA , May 20, 2013  Atlantic ... developed and is commercializing a unique technology to ... founder and President, Anthony Soscia ... the Atlanta Business Chronicle ,s Health-Care Heroes ... Atlanta Business Chronicle to honor individuals and ...
(Date:5/20/2013)... May 20, 2013 Enrollment of patients with ... 2b dose-finding clinical trial of product candidate NewMet ... treatment for Type 2 diabetes. Elcelyx expects to complete ... in June. Results of the trial,s primary endpoint of ... summer, and the read-out for long-term glucose lowering and ...
(Date:5/20/2013)... Md. , May 20, 2013  Neuralstem, Inc. ... Feldman , MD, PhD, principal investigator, presented updated ... stem cell (NSI-566) trial in the treatment of amyotrophic ... ,s disease) at the neuro diabetes special medical symposium ... In a talk called "Recent Therapeutic Advances in Stem ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... contact lens cleaning solution is ... and professionally proven cleaner. A ... resulting in a very effective ... cosmetic residue, salts, mucous and ...
Round knurled handle. Overall length 130 mm....
Alvis foreign body spud 4 3/4 inches, oval curette 1 x 3 mm with fine point....
Foreign body spud angled, lightly rounded tip....
Medicine Products: